Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05916495
Other study ID # LTX patientMpower 01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 29, 2023
Est. completion date December 2024

Study information

Verified date November 2023
Source University of Manchester
Contact Rebecca Borton
Phone +442033224121
Email researchoffice@patientmpower.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lung transplantation is used to treat patients with lung damage when there is no other treatment option. Patients require close monitoring following their transplant, with hospital check-ups every 3-4 months usually lasting all day. Although check-ups often result in no change to patient management they are essential as patients have better outcomes if complications are detected quickly. The aim is to explore whether remote monitoring via an app (patientMpower) ± questionnaire (specifically designed to assess post-transplant patients' health), linked to a device to measure lung function, could replace some check-ups for lung transplant patients. Patients will be randomised to receive either normal care or remote monitoring (i.e. their symptoms will be evaluated using home spirometry combined with a questionnaire). 100 lung transplant recipients will be enrolled with 50 patients being assigned to either group. Health outcomes and costs of care between the two groups will be compared


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hybrid care arm
Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
Standard of care arm
Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).

Locations

Country Name City State
United Kingdom Manchester University NHS Foundation Trust Manchester

Sponsors (5)

Lead Sponsor Collaborator
University of Manchester Manchester University NHS Foundation Trust, New Start, The Wythenshawe Hospital Transplant Fund Centre, patientMpower Ltd., University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of clinic visits per patient The number of clinic follow up visits in the observation period 6 months
Secondary Number of unplanned clinic visits per patient The number of unplanned clinic visits in the observation period 6 months
Secondary "Measuring the Utilization Rate of Remote Monitoring for Patient Engagement" "Measuring the Utilization Rate of Remote Monitoring for Patient Engagement" Number of patient interactions with the remote monitoring platform Frequency of use at = 1 day/week 6 months
Secondary Hospitalisation due to deterioration of allograft function Number of patients hospitalised due to deterioration of allograft function 6 Months
Secondary Duration of hospitalisations due to deterioration of allograft function Number of hospitalised days due to deterioration of allograft function 6 Months
Secondary Number of planned clinic visits per patient The number of planned clinic visits in the observation period 6 Months
Secondary Number of patients where symptoms were recorded accurately on the questionnaire The number of patients where a clinician recorded that symptoms were recorded accuratly 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05526950 - Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) N/A
Enrolling by invitation NCT05950724 - RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Early Phase 1
Active, not recruiting NCT05505422 - Routine Versus Selective Intraoperative ECMO in Lung Transplant N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Enrolling by invitation NCT04522388 - Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant N/A
Completed NCT04165161 - Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography N/A
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Withdrawn NCT03258801 - Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Completed NCT04892719 - 4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation N/A
Completed NCT03221764 - Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients Phase 2
Active, not recruiting NCT04975607 - Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study N/A
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT03367221 - Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist N/A
Recruiting NCT03276403 - Primary Graft Dysfunction Score in Lung Transplantation N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT05242289 - Cytokine Adsorption in Lung Transplantation N/A
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Not yet recruiting NCT04377139 - Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Not yet recruiting NCT06399302 - Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
Terminated NCT03562416 - Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects Phase 2